Posttreatment human papillomavirus testing for recurrent cervical intraepithelial neoplasia: a systematic review

American Journal of Obstetrics and Gynecology

Volumn 200, Issue 4, 2009, Pages 422.e1-422.e9

  Chan, Benjamin K S ^a   Melnikow, Joy ^b   Slee, Christina A ^b   Arellanes, Rose ^c   Sawaya, George F ^d  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c KAISER PERMANENTE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

cervical intraepithelial neoplasia; colposcopy; Hybrid Capture 2; metaanalysis; papillomavirus

Indexed keywords

ARTICLE; CANCER DIAGNOSIS; COLPOSCOPY; CYTOLOGY; DIAGNOSTIC VALUE; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; MEDLINE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECURRENT CANCER; UTERINE CERVIX CARCINOMA IN SITU; VIRUS DETECTION; WART VIRUS;

EID: 62549154889     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2008.11.031     Document Type: Article

References (55)

1. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No.: 66. Management of abnormal cervical cytology and histology. Obstet Gynecol 106 (2005) 645-664
2. Wright Jr. T.C., Massad L.S., Dunton C.J., Spitzer M., Wilkinson E.J., and Solomon D. 2006 Consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ. Am J Obstet Gynecol 197 (2007) 340-345
3. Arbyn M., Sasieni P., Meijer C.J., Clavel C., Koliopoulos G., and Dillner J. Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses. Vaccine 24 suppl (2006) S78-S89
4. Paraskevaidis E., Arbyn M., Sotiriadis A., et al. The role of HPV DNA testing in the follow-up period after treatment for CIN: a systematic review of the literature. Cancer Treat Rev 30 (2004) 205-211
5. Zielinski G.D., Bais A.G., Helmerhorst T.J., et al. HPV testing and monitoring of women after treatment of CIN 3: review of the literature and meta-analysis. Obstet Gynecol Surv 59 (2004) 543-553
6. Iftner T., and Villa L.L. Chapter 12: Human papillomavirus technologies. J Natl Cancer Inst Monogr (2003) 80-88
7. Koliopoulos G., Arbyn M., Martin-Hirsch P., Kyrgiou M., Prendiville W., and Paraskevaidis E. Diagnostic accuracy of human papillomavirus testing in primary cervical screening: a systematic review and meta-analysis of non-randomized studies. Gynecol Oncol 104 (2007) 232-246
8. Kreimer A.R., Guido R.S., Solomon D., et al. Human papillomavirus testing following loop electrosurgical excision procedure identifies women at risk for posttreatment cervical intraepithelial neoplasia grade 2 or 3 disease. Cancer Epidemiol Biomarkers Prev 15 (2006) 908-914
9. Alonso I., Torne A., Puig-Tintore L.M., et al. Pre- and post-conization high-risk HPV testing predicts residual/recurrent disease in patients treated for CIN 2-3. Gynecol Oncol 103 (2006) 631-636
10. Verguts J., Bronselaer B., Donders G., et al. Prediction of recurrence after treatment for high-grade cervical intraepithelial neoplasia: the role of human papillomavirus testing and age at conisation. BJOG 113 (2006) 1303-1307
11. Wright Jr. T.C., Massad L.S., Dunton C.J., Spitzer M., Wilkinson E.J., and Solomon D. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol 197 (2007) 346-355
12. Bollen L.J., Tjong A.H.S.P., van der Velden J., et al. Clearance of cervical human papillomavirus infection by treatment for cervical dysplasia. Sex Transm Dis 24 (1997) 456-460
13. Ho G.Y., Burk R.D., Klein S., et al. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst 87 (1995) 1365-1371
14. Molden T., Nygard J.F., Kraus I., et al. Predicting CIN2+ when detecting HPV mRNA and DNA by PreTect HPV-proofer and consensus PCR: a 2-year follow-up of women with ASCUS or LSIL Pap smear. Int J Cancer 114 (2005) 973-976
15. Molden T., Kraus I., Karlsen F., Skomedal H., Nygard J.F., and Hagmar B. Comparison of human papillomavirus messenger RNA and DNA detection: a cross-sectional study of 4,136 women >30 years of age with a 2-year follow-up of high-grade squamous intraepithelial lesion. Cancer Epidemiol Biomarkers Prev 14 (2005) 367-372
16. Perrons C., Brink N., Jalal H., Watts P., and Jelley R. The impact of high risk human papillomavirus testing in an inner London colposcopy clinic. J Med Virol 76 (2005) 576-582
17. Hernadi Z., Szoke K., Sapy T., et al. Role of human papillomavirus (HPV) testing in the follow-up of patients after treatment for cervical precancerous lesions. Eur J Obstet Gynecol Reprod Biol 118 (2005) 229-234
18. Kanamori Y., Kigawa J., Minagawa Y., et al. Residual disease and presence of human papillomavirus after conization. Oncology 55 (1998) 517-520
19. Soderlund-Strand A., Rymark P., Andersson P., Dillner J., and Dillner L. Comparison between the Hybrid Capture II test and a PCR-based human papillomavirus detection method for diagnosis and posttreatment follow-up of cervical intraepithelial neoplasia. J Clin Microbiol 43 (2005) 3260-3266
20. Izumi T., Kyushima N., Genda T., et al. Margin clearance and HPV infection do not influence the cure rates of early neoplasia of the uterine cervix by laser conization. Eur J Gynaecol Oncol 21 (2000) 251-254
21. Kucera E., Sliutz G., Czerwenka K., Breitenecker G., Leodolter S., and Reinthaller A. Is high-risk human papillomavirus infection associated with cervical intraepithelial neoplasia eliminated after conization by large-loop excision of the transformation zone?. Eur J Obstet Gynecol Reprod Biol 100 (2001) 72-76
22. Elfgren K., Bistoletti P., Dillner L., Walboomers J.M., Meijer C.J., and Dillner J. Conization for cervical intraepithelial neoplasia is followed by disappearance of human papillomavirus deoxyribonucleic acid and a decline in serum and cervical mucus antibodies against human papillomavirus antigens. Am J Obstet Gynecol 174 (1996) 937-942
23. Sutton A.J., Abrams K.R., Jones D.R., Sheldon T.A., and Song F. Methods for meta-analysis in medical research (2000), John Wiley & Sons, Inc, Chichester, UK
24. Reitsma J.B., Glas A.S., Rutjes A.W.S., Scholten R.J.P.M., Bossuyt P.M., and Zwinderman A.H. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol 58 (2005) 982-990
25. Harbord R.M., Deeks J.J., Egger M., Whiting P., and Sterne J.A.C. A unification of models for meta-analysis of diagnostic accuracy studies. Biostatistics 8 (2007) 239-251
26. Pinheiro J., Bates D., DebRoy S., Sarkar D., and R Core team. NLME: linear and nonlinear mixed effects models (2007)
27. R Development Core Team. R: a language and environment for statistical computing (computer software) (2006), R Foundation for Statistical Computing, Vienna, Austria
28. Higgins J.P.T., and Thompson S.G. Quantifying heterogeneity in a meta-analysis. Stat Med 21 (2002) 1539-1558
29. Bar-Am A., Gamzu R., Levin I., Fainaru O., Niv J., and Almog B. Follow-up by combined cytology and human papillomavirus testing for patients post-cone biopsy: results of a long-term follow-up. Gynecol Oncol 91 (2003) 149-153
30. Bae J.H., Kim C.J., Park T.C., Namkoong S.E., and Park J.S. Persistence of human papillomavirus as a predictor for treatment failure after loop electrosurgical excision procedure. Int J Gynecol Cancer 17 (2007) 1271-1277
31. Bodner K., Bodner-Adler B., Wierrani F., Kimberger O., Denk C., and Grunberger W. Is therapeutic conization sufficient to eliminate a high-risk HPV infection of the uterine cervix?. A clinicopathological analysis. Anticancer Res 22 (2002) 3733-3736
32. Houfflin Debarge V., Collinet P., Vinatier D., et al. Value of human papillomavirus testing after conization by loop electrosurgical excision for high-grade squamous intraepithelial lesions. Gynecol Oncol 90 (2003) 587-592
33. Sarian L.O., Derchain S.F., Andrade L.A., Tambascia J., Morais S.S., and Syrjanen K.J. HPV DNA test and Pap smear in detection of residual and recurrent disease following loop electrosurgical excision procedure of high-grade cervical intraepithelial neoplasia. Gynecol Oncol 94 (2004) 181-186
34. Zielinski G.D., Rozendaal L., Voorhorst F.J., et al. HPV testing can reduce the number of follow-up visits in women treated for cervical intraepithelial neoplasia grade 3. Gynecol Oncol 91 (2003) 67-73
35. Acladious N.N., Sutton C., Mandal D., Hopkins R., Zaklama M., and Kitchener H. Persistent human papillomavirus infection and smoking increase risk of failure of treatment of cervical intraepithelial neoplasia (CIN). Int J Cancer 98 (2002) 435-439
36. Bekkers R.L., Melchers W.J., Bakkers J.M., et al. The role of genotype-specific human papillomavirus detection in diagnosing residual cervical intraepithelial neoplasia. Int J Cancer 102 (2002) 148-151
37. Cecchini S., Carozzi F., Confortini M., Zappa M., and Ciatto S. Persistent human papilloma virus infection as an indicator of risk of recurrence of high-grade cervical intraepithelial neoplasia treated by the loop electrosurgical excision procedure. Tumori 90 (2004) 225-228
38. Chua K.L., and Hjerpe A. Human papillomavirus analysis as a prognostic marker following conization of the cervix uteri. Gynecol Oncol 66 (1997) 108-113
39. Cruickshank M.E., Sharp L., Chambers G., Smart L., and Murray G. Persistent infection with human papillomavirus following the successful treatment of high grade cervical intraepithelial neoplasia. BJOG 109 (2002) 579-581
40. Elfgren K., Jacobs M., Walboomers J.M., Meijer C.J., and Dillner J. Rate of human papillomavirus clearance after treatment of cervical intraepithelial neoplasia. Obstet Gynecol 100 (2002) 965-971
41. Nagai N., Mukai K., Oshita T., Shiroyama Y., and Ohama K. Human papillomavirus DNA status after loop excision for cervical intraepithelial neoplasia grade III: a prospective study. Int J Mol Med 13 (2004) 589-593
42. Nagai Y., Maehama T., Asato T., and Kanazawa K. Persistence of human papillomavirus infection after therapeutic conization for CIN 3: is it an alarm for disease recurrence?. Gynecol Oncol 79 (2000) 294-299
43. Nobbenhuis M.A., Meijer C.J., van den Brule A.J., et al. Addition of high-risk HPV testing improves the current guidelines on follow-up after treatment for cervical intraepithelial neoplasia. Br J Cancer 84 (2001) 796-801
44. Paraskevaidis E., Koliopoulos G., Alamanos Y., Malamou-Mitsi V., Lolis E.D., and Kitchener H.C. Human papillomavirus testing and the outcome of treatment for cervical intraepithelial neoplasia. Obstet Gynecol 98 (2001) 833-836
45. Strander B., Ryd W., Wallin K.L., et al. Does HPV-status 6-12 months after treatment of high grade dysplasia in the uterine cervix predict long term recurrence?. Eur J Cancer 43 (2007) 1849-1855
46. Hellsten C., Sjostrom K., and Lindqvist P.G. A 2-year follow-up study of anxiety and depression in women referred for colposcopy after an abnormal cervical smear. BJOG 115 (2008) 212-218
47. Basen-Engquist K., Fouladi R.T., Cantor S.B., et al. Patient assessment of tests to detect cervical cancer. Int J Technol Assess Health Care 23 (2007) 240-247
48. Hellsten C., Sjostrom K., and Lindqvist P.G. A prospective Swedish cohort study on psychosocial factors influencing anxiety in women referred for colposcopy. BJOG 114 (2007) 32-38
49. Maissi E., Marteau T.M., Hankins M., Moss S., Legood R., and Gray A. The psychological impact of human papillomavirus testing in women with borderline or mildly dyskaryotic cervical smear test results: 6-month follow-up. Br J Cancer 92 (2005) 990-994
50. Cuzick J., Clavel C., Petry K.U., et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 119 (2006) 1095-1101
51. Bulkmans N.W., Berkhof J., Rozendaal L., et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 370 (2007) 1764-1772
52. Mayrand M.H., Duarte-Franco E., Rodrigues I., et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 357 (2007) 1579-1588
53. Naucler P., Ryd W., Tornberg S., et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 357 (2007) 1589-1597
54. Ronco G., Brezzi S., Carozzi F., et al. The New Technologies for Cervical Cancer Screening randomised controlled trial: an overview of results during the first phase of recruitment. Gynecol Oncol 107 (2007) S230-S232
55. Cantor S.B., Cardenas-Turanzas M., Cox D.D., et al. Accuracy of colposcopy in the diagnostic setting compared with the screening setting. Obstet Gynecol 111 (2008) 7-14